Study of OT202 in Treating Moderate to Severe Dry Eye

A Phase II, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of OT202 Eye Drops in the Treatment of Moderate to Severe Dry Eye

This is a phase II study to explore the optimal dosage of OT202 in treating dry eye.

Study Overview

• Status: Completed
• Conditions: Dry Eye
• Intervention / Treatment: Drug: OT202 conc 0.5%; Drug: OT202 conc 0.1%; Drug: Placebo

Detailed Description

Subjects successfully enrolled will enter a 2-week induction period of OT202 solvent eye drops, treated with OT202 three times daily (morning, afternoon, and evening), with 1-2 drops each time. On the day of the baseline visit (Visit 2), subjects will be assessed again to meet the inclusion and exclusion criteria. Subjects remain in the study are then randomized with a 1:1:1 ratio to 3 groups, the 0.5% OT202 eye drop group, 1% OT202 eye drop group, or OT202 solvent eye drop group, for an 8-week treatment period. Safety visits will be conducted 2 weeks after completion of the respective treatment.

• Study Type: Interventional
• Enrollment (Actual): 213
• Phase: Phase 2

Contacts and Locations

Study Locations

• China
  • Changsha, China
    • The Third XIANGYA Hospital of Central South University
  • Hangzhou, China
    • The Second Affiliated Hospital Zhejiang University School of Medicine
  • Kunming, China
    • Then Second People's Hospital of Yunnan Province
  • Ningbo, China
    • Ning Bo Eye Hospital
  • Tianjin, China
    • Tianjin Eye Hospital
  • Tianjin, China
    • Tianjin Medical University Eye Hospital
  • Wenzhou, China
    • Eye Hospital, WMU
  • Wuhan, China
    • Renmin Hospital of Wuhan University
  • Wuhan, China
    • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
  • Xi'an, China
    • The First Affiliated Hospital of Xi'an Jiaotong University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

---Inclusion Criteria ---

1. 18 to 75 years of age (inclusive) at the time of signing the ICF, either sex or ethnic group.

2. With history of dry eye for at least 6 months prior to screening, and history of use or willingness to use eye drops for the treatment of dry eye within 6 months prior to screening

   .

3. Binocular BCVA ≥ 0.25 decimals (standard logarithmic visual acuity chart) at Screening and Baseline.

4. At least one eye (the same eye) meets all the following criteria at screening and baseline:

   • TCSS ≥ 2 points
   • Eye dryness score (EDS) ≥ 40 points in VAS
   • Conjunctival hyperemia score ≥ 1 point
   • TFBUT ≤ 5 seconds
   • 1 mm/5 min ≤ Schirmer I test (without surface anesthesia) ≤ 10 mm/5 min
5. Must be able to understand and sign the ICF approved by Independent Ethics Committee (EC).
6. Willing and able to conduct protocol-required study visits, follow study guidelines, and take study drug as instructed.

---Exclusion Criteria ---

1. With contraindication or hypersensitivity to the study drug (OT202 and excipients) or diagnostic reagents (fluorescein sodium, lissamine green, etc.).
2. During the screening period and baseline period, any eye with ocular active inflammation or structural abnormalities that may affect the trial assessment, including but not limited to trichiasis, blepharospasm, blepharitis, meibomitis, severe meibomian gland dysfunction, bulbar conjunctival laxity, keratitis, recurrent corneal erosion, allergic conjunctivitis, iritis, anterior chamber inflammation, known retinal detachment, diabetic retinopathy, or history of any progressive retinal disease.
3. With history of possible or confirmed ocular infection (bacterial, viral, or fungal) or ocular herpes (simple or zoster) in either eye, as determined by the patient's medical history and/or at the screening and baseline examinations.
4. Those with intraocular pressure (non-contact tonometry) greater than 21 mmHg or less than 8 mmHg or diagnosed with glaucoma at screening and baseline, or those with ocular hypertension who underwent intraocular pressure reduction therapy, and those with a history or suspicion of glaucoma.
5. Those with any systemic disease expected to potentially affect the study results. It include but is not limited to Sjögren syndrome, Stevens-Johnson syndrome, rheumatoid arthritis, graft versus host disease, systemic lupus erythematosus, scleroderma, sarcoidosis, herpes, acne, rosacea, etc.
6. Those who cannot stop using any ocular medication or treatment during the clinical trial.
7. Those with recent clinically relevant history (e.g., hepatic, renal impairment) within 6 months prior to screening or current severe, unstable, or uncontrolled cardiovascular, pulmonary, hepatic, renal, autoimmune, and other relevant systemic diseases (e.g., severe chronic obstructive pulmonary disease, arrhythmia, significant heart failure, uncontrolled hypertension, type 2 diabetes mellitus), as assessed by the investigator.
8. Those on a chronic, systemic medication regimen used for less than 1 month at screening and baseline or with dose changed within 1 month (including initiation of new medication and discontinuation).

9. Those who have used any prohibited medications (topical ocular, systemic, and/or injectable medications) during the specified period prior to screening. These medications are also prohibited during the study. However, if a subject has a prohibited medication at screening, it needs to be stopped and washed out according to the washout period specified below, which can be included in the wash-out period. The minimum reasonable washout period for prohibited medications is as follows:

   • Systemic and local immunosuppressant and immunotherapy (such as cyclosporine eye drops, tacrolimus eye drops, etc.): 60 days;
   • Corticosteroids (any route): 14 days;
   • Systemic or ocular topical mast cell stabilizers, antihistamines, antihistamines/mast cell stabilizer combination, vasoconstrictors, monoamine oxidase inhibitors: 7 days;
   • Other topical ophthalmic preparations (including artificial tears): 3 days;
   • Medications known to cause ocular dryness (e.g., anticholinergics, serotonin reuptake inhibitors, beta-blockers, diuretics, etc.): 14 days.

   Note:Non-periocular, low-potency, over-the-counter corticosteroid topical skin creams are allowed for use in the study (e.g., hydrocortisone butyrate cream/ointment).

10. Previous use of spleen tyrosine kinase (Syk) inhibitors or eye drop products targeting the same as anti-vascular endothelial growth factor (VEGF).
11. Those who wore corneal contact lenses within 7 days prior to screening or required them during the study.
12. Those who underwent meibomian gland massage or moist chamber therapy within 7 days prior to screening, or non-drug therapies for dry eye such as intense pulsed light therapy, thermal pulsation therapy, etc., within the previous 6 months before screening.
13. Those who previously underwent dry eye surgery such as tear duct embolization (current tear duct embolization status or punctal plug use in the past 6 months) or amniotic membrane transplantation.
14. Those who underwent ocular surface surgery (e.g., LASIK excimer laser in situ keratomileusis) within 12 months prior to screening or intraocular surgery within 6 months prior to screening in either eye, as determined by the subject's medical history and/or examination, or anticipated ocular surgery during the study.
15. Those who use other investigational products or devices within 3 months prior to screening or concurrently during the study.
16. Non-compliance with drug administration (< 80% or > 120%) during the introduction period.
17. Females of childbearing potential who are currently pregnant, or have a positive pregnancy test result, or plan to get pregnant during the study, or are currently breastfeeding, or do not agree to use appropriate contraception methods to avoid pregnancy during the study period up to 1 month after the last dose of study drug.
18. Males who do not agree to use one or more acceptable effective contraception methods during the study period up to 1 month after the last dose of study drug.
19. Any condition or situation that, in the opinion of the investigator, may pose a safety risk to the subject in the trial or may interfere with the conduct of the study, or the investigator believes that the subject may not be able to complete or comply with the requirements of the study (due to administrative reasons or otherwise).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: OT202 conc.0.5% group; Administered three times daily (morning, afternoon, and evening), with 1-2 drops each time, instilled into the conjunctival sac.	Drug: OT202 conc 0.5%; Apply 1-2 drops of OT202 0.5% solution into the conjunctival sac. three times daily; Other Names: Investigational product
Experimental: OT202 conc. 0.1% group; Administered three times daily (morning, afternoon, and evening), with 1-2 drops each time, instilled into the conjunctival sac.	Drug: OT202 conc 0.1%; Apply 1-2 drops of OT202 0.1% solution into the conjunctival sac. three times daily; Other Names: Investigational product
Experimental: Placebo group; Administered three times daily (morning, afternoon, and evening), with 1-2 drops each time, instilled into the conjunctival sac.	Drug: Placebo; Apply 1-2 drops of placebo solution into the conjunctival sac. three times daily

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Total Corneal Fluorescein Staining (TCSS) score	Compare the difference of changes in TCSS relative to baseline of three study groups on day 56.	Day 56

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Visual Analogue Scale (VAS) Score	Compare the difference of changes in VAS scale relative to baseline of three study groups on day 28 & 56.	DAY 28 & 56
Ocular Surface Disease Index (OSDI) Score	Compare the DAY 28 & 56 OSDI scale results of the subjects with the baseline results.	Day 28 & 56
Conjunctive Hyperemia	Compare the DAY 28 & 56 Conjunctive Hyperemia data of the subjects with the baseline data.	Day 28 & 56
Corneal Staining	Compare the DAY 28 & 56 Corneal Staining data of the subjects with the baseline data.	Day 28 & 56
A dry eye syndrome questionnaire - Symptom Assessment iN Dry Eye(SANDE)	Compare the DAY 28 & 56 SANDE scale results of the subjects with baseline .	Day 28 & 56
Tear Film Breakup-time (TFBUT)	Compare the DAY 28 & 56 TFBUT scale results of the subjects with baseline .	Day 28 & 56
Schirmer I Test	Compare the DAY 28 & 56 Schirmer I Test scale results of the subjects with baseline .	Day 28 & 56

Collaborators and Investigators

• Sponsor: Ocumension Therapeutics (Shanghai) Co., Ltd
• Investigators: Principal Investigator: Wei Chen, Eye Hospital, WMU; Study Director: Jialu Xia, Sponsor GmbH

Study record dates

Study Major Dates

• Study Start (Actual): April 10, 2023
• Primary Completion (Actual): January 26, 2024
• Study Completion (Actual): January 26, 2024

Study Registration Dates

• First Submitted: May 20, 2024
• First Submitted That Met QC Criteria: May 23, 2024
• First Posted (Actual): May 30, 2024

Study Record Updates

• Last Update Posted (Actual): May 30, 2024
• Last Update Submitted That Met QC Criteria: May 23, 2024
• Last Verified: May 1, 2024

More Information

Terms related to this study

• Keywords: Severe dry eye; Moderate dry eye
• Additional Relevant MeSH Terms: Eye Diseases; Lacrimal Apparatus Diseases; Keratoconjunctivitis; Conjunctivitis; Conjunctival Diseases; Keratitis; Corneal Diseases; Dry Eye Syndromes; Keratoconjunctivitis Sicca
• Other Study ID Numbers: OT202-02-01

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No